Ekso Bionics price target lowered to $9.25 from $10 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Ekso Bionics to $9.25 from $10 and keeps a Buy rating on the shares. Ekso’s Q4 revenues were in line with consensus estimates, while its net loss of (22c) per share was below estimates, the analyst tells investors in a research note. The firm says EksoHealth remains strong and is projecting lower operating expenses in 2024 and beyond.